Articles
WASHINGTON, DC—New biomarkers for urologic cancers should help clinicians not only diagnose prostate and bladder cancers but also help them distinguish between indolent and aggressive disease. Urologists and oncologists learned about 3 new biomarkers for prostate cancer at the 2011 annual meeting of the American Urological Association, held this week in Washington, DC.
Read More ›
By replacing CA 125 with a multivariate index assay (OVA1 blood test, Vermillion Inc), researchers showed the potential of a modified version of the American College of Obstetricians and Gynecologists guidelines to identify more ovarian malignancies before surgery. The modified guidelines detected almost 80% of all missed malignancies and more than 90% of missed epithelial ovarian cancers. The new guidelines, however, decreased specificity and positive predictive value.
Read More ›
Impaired Hydroxylation of 5-Methylcytosine in TET2-Mutated Myeloid Malignancies
Read More ›
Serum Albumin Affects Methotrexate Level Variability and Methotrexate Toxicity
Read More ›
ACOSOG Z1031: Neoadjuvant Comparison between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Rich Stage 2/3 Breast Cancer
Read More ›
BOSTON—Nurses have been involved in radiation oncology since the early 1940s, but as nursing roles in general have evolved over time, so has the role of these nurses. A group of advanced practice nurses (APNs) shared how they came to be part of their facility’s radiation oncology department and how the increased strain on healthcare is opening opportunities in this field for APNs.
Read More ›
BOSTON—As more targeted therapies for non–small-cell lung cancer (NSCLC) become available, experts are assessing which patients’ tumors should be genotyped and when. Although genotyping—not to be confused with genetic testing—is becoming increasingly important in developing a treatment plan, professional guidelines do not yet recommend incorporating it as a routine part of care for patients with NSCLC.
Read More ›
BOSTON—Recognizing steroid-induced hyperglycemia early and addressing it promptly can prevent significant adverse effects associated with this complication. Educating patients on the importance of and methods for maintaining good blood glucose control helps mitigate damage to the vascular system and kidneys from hyperglycemia. It also lessens susceptibility to infection, a complication of hyperglycemia that is of serious concern in immunocompromised patients.
Read More ›
In a multicenter, randomized, phase 2/3 trial, the 4-drug combination oxaliplatin/irinotecan/fluorouracil/leucovorin (FOLFIRINOX) prolonged median overall and progression-free survival and increased the overall response rate compared with gemcitabine, the reference standard, for patients with metastatic pancreatic adenocarcinoma and good performance status (0-1). However, the combination regimen was associated with more adverse events, especially febrile neutropenia, and a decrease in quality of life.
Read More ›